AMENDMENTS TO THE CLAIMS

1. (Currently amended) A pharmaceutical composition comprising amorphous cefditoren pivoxil and a sucrose ~~ester~~ fatty acid ester, which is obtainable by mixing or wet-granulating particles containing amorphous cefditoren pivoxil with the sucrose ~~ester~~ fatty acid ester while amorphous cefditoren pivoxil maintains its particle state, wherein crystallization of the amorphous cefditoren pivoxil is inhibited.

2. (Currently amended) The pharmaceutical composition according to claim 1, wherein the weight ratio of the sucrose fatty acid ester to the cefditoren pivoxil is in a range of from 0.0008 to 0.816 ~~which contains 0.1 to 100 mg of the sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil~~.

3. (Previously presented) The pharmaceutical composition according to claim 1, which further comprises a pharmaceutically acceptable polymer.

4. (Previously presented) The pharmaceutical composition according to claim 3, wherein the polymer is one or more water-soluble high polymers selected from the group consisting of hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

5. (Currently amended) The pharmaceutical composition according to claim 3, wherein the weight ratio of the polymer to the cefditoren pivoxil is in a range of from 0.008 to 0.816~~which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil~~.

6. (Previously presented) The pharmaceutical composition according to claim 1, which further comprises one or more pharmaceutically acceptable additives.

7. (Previously presented) The pharmaceutical composition according to claim 2, which further comprises a pharmaceutically acceptable polymer.

8. (Previously presented) The pharmaceutical composition according to claim 7, wherein the polymer is one or more water-soluble high polymers selected from the group consisting of hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

9. (Currently amended) The pharmaceutical composition according to claim 4, wherein the weight ratio of the polymer to the cefditoren pivoxil is in a range of from 0.008 to 0.816~~which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil~~.

10. (Currently amended) The pharmaceutical composition according to claim 7, wherein the weight ratio of the polymer to the cefditoren pivoxil is in a range of from 0.008 to 0.816~~which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil~~.

11. (Currently amended) The pharmaceutical composition according to claim 8, wherein the weight ratio of the polymer to the cefditoren pivoxil is in a range of from 0.008 to 0.816~~which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil~~.

12. (Previously presented) The pharmaceutical composition according to claim 2, which further comprises one or more pharmaceutically acceptable additives.

13. (Previously presented) The pharmaceutical composition according to claim 3, which further comprises one or more pharmaceutically acceptable additives.

14. (Previously presented) The pharmaceutical composition according to claim 4,

which further comprises one or more pharmaceutically acceptable additives.

15. (Previously presented) The pharmaceutical composition according to claim 7, which further comprises one or more pharmaceutically acceptable additives.

16. (Previously presented) The pharmaceutical composition according to claim 8, which further comprises one or more pharmaceutically acceptable additives.

17. (Previously presented) The pharmaceutical composition according to claim 9, which further comprises one or more pharmaceutically acceptable additives.

18. (Previously presented) The pharmaceutical composition according to claim 10, which further comprises one or more pharmaceutically acceptable additives.

19. (Previously presented) The pharmaceutical composition according to claim 11, which further comprises one or more pharmaceutically acceptable additives.

20. (Currently amended) A pharmaceutical composition comprising particles having amorphous cefditoren pivoxil present in an interior portion of said particles and a sucrose ~~ester~~ fatty acid ester present in an exterior portion of said particles, wherein crystallization of amorphous cefditoren pivoxil is inhibited.

21. (Currently amended) The pharmaceutical composition of claim 20, wherein the sucrose ~~ester~~ fatty acid ester has a hydrophilic to lipophilic balance (HLB) value greater than 10.

22. (Currently amended) The pharmaceutical composition of claim 20, wherein said sucrose ~~ester~~ fatty acid ester has an HLB value in a range of from 11 to 20.

23. (Previously presented) The pharmaceutical composition of claim 20, further comprising a pharmaceutically acceptable polymer.

24. (Previously presented) The pharmaceutical composition of claim 23, wherein said pharmaceutically acceptable polymer includes at least one polymer selected from the group consisting of hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

25. (Previously presented) The pharmaceutical composition according to claim 20, in a dose form containing from about 300 to 800 milligrams of amorphous cefditoren pivoxil.

26. (Previously presented) The pharmaceutical composition of claim 20 in a tableted dose form.

27-30. (Cancelled)

31. (Currently amended) The pharmaceutical composition according to claim 1, wherein the sucrose ~~ester~~ fatty acid ester has an HLB value of 11 to 20.

32. (Previously presented) The pharmaceutical composition according to claim 1, wherein the composition is free from polysorbate 80.

33. (Previously presented) The pharmaceutical composition according to claim 1, which has an amorphousness-retaining character of the amorphous cefditoren pivoxil in aqueous medium of at least one day.

34. (Previously presented) The pharmaceutical composition according to claim 1, which has an amorphousness-retaining character of the amorphous cefditoren pivoxil in aqueous medium of at least two days.

35. (Currently amended) The pharmaceutical composition according to claim 20, wherein the sucrose ~~ester~~ fatty acid ester has an HLB value of 11 to 20.

36. (Previously presented) The pharmaceutical composition according to claim 20, wherein the composition is free from polysorbate 80.

37. (Previously presented) The pharmaceutical composition according to claim 20, which has an amorphousness-retaining character of the amorphous cefditoren pivoxil in aqueous medium of at least one day.

38. (Previously presented) The pharmaceutical composition according to claim 20, which has an amorphousness-retaining character of the amorphous cefditoren pivoxil in aqueous medium of at least two days.

39. (New) A pharmaceutical composition comprising amorphous cefditoren pivoxil and sucrose fatty acid ester, wherein the weight ratio of the sucrose fatty acid ester to the amorphous cefditoren pivoxil is in a range of from 0.0008 to 0.04, and wherein the composition is capable of retaining the amorphicity of said amorphous cefditoren pivoxil in aqueous medium for at least one day.

40. (New) A pharmaceutical composition comprising amorphous cefditoren pivoxil in combination with an amount of sucrose fatty acid ester that is effective to maintain said amorphous cefditoren pivoxil in an amorphous state in aqueous medium for a period of at least one day.